[Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
The aim of this study was to evaluate three recently marketed putative mesothelioma-binding antibodies, calretinin, HBME-1 and thrombomodulin, and two putative adenocarcinoma-binding antibodies, AUA1 and MOC31, on paraffin sections from 28 mesotheliomas and 30 adenocarcinomas. Moreover, the expression of ACE, BerEP4, CA125, CA19.9, LeuM1 and vimentin was assessed. Calretinin, HBME-1 and thrombomodulin, which showed a 100%, 89% and 43% sensitivity, and a 50%, 70% and 87% specificity for mesothelioma respectively, were less efficient than vimentin (100% specificity and 67% sensitivity) for the positive identification of mesothelioma. AUA1, BerEP4 and MOC31 were 100% sensitive to adenocarcinoma, with BerEP4 and MOC31 having the highest specificity (86% each). The immunophenotype "vimentin-positive, ACE-negative, CA19.9-negative" yielded 100% sensitivity and 97% specificity for diagnosis of mesothelioma. We advocate the use of the four-marker panel of ACE, CA19.9, MOC31 (or BerEP4) and vimentin for differentiating mesothelioma from adenocarcinoma.
Chenard-Neu
M P
MP
Service d'Anatomie Pathologique, CHRU de Strasbourg-Hautepierre.
Kabou
A
A
Mechine
A
A
Brolly
F
F
Orion
B
B
Bellocq
J P
JP
D000230:Adenocarcinoma / Q000737:chemistry / Q000175:diagnosis*; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis*; D018395:CA-19-9 Antigen / Q000032:analysis; D064032:Calbindin 2; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000737:chemistry / Q000175:diagnosis*; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000032:analysis; D064030:S100 Calcium Binding Protein G / Q000276:immunology; D018180:Thrombomodulin / Q000276:immunology; D014746:Vimentin / Q000032:analysis
D000906:Antibodies; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; C576764:CALB2 protein, human; D064032:Calbindin 2; D064030:S100 Calcium Binding Protein G; D018180:Thrombomodulin; D014746:Vimentin; D007703:Peptidyl-Dipeptidase A